I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Dovitinib in patients with gastrointestinal stromal tumour ..:
Joensuu, Heikki
;
Blay, Jean-Yves
;
Comandone, Alessandro
...
10.1038/bjc.2017.290. , 2017
Link:
http://hdl.handle.net/10138/228557
RT Journal T1
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
UL https://suche.suub.uni-bremen.de/peid=base-ftunivhelsihelda:oai:helda.helsinki.fi:10138_228557&Exemplar=1&LAN=DE A1 Joensuu, Heikki A1 Blay, Jean-Yves A1 Comandone, Alessandro A1 Martin-Broto, Javier A1 Fumagalli, Elena A1 Grignani, Giovanni A1 Del Muro, Xavier Garcia A1 Adenis, Antoine A1 Valverde, Claudia A1 Pousa, Antonio Lopez A1 Olivier, Bouche A1 Italiano, Antoine A1 Bauer, Sebastian A1 Barone, Carlo A1 Weiss, Claudia A1 Crippa, Stefania A1 Camozzi, Maura A1 Castellana, Ramon A1 Le Cesne, Axel PB Nature Publishing Group YR 2017 K1 dovitinib K1 gastrointestinal stromal tumour K1 GIST K1 imatinib K1 refractory K1 TYROSINE KINASE INHIBITOR K1 KIT MUTATIONS K1 PHASE-II K1 SUNITINIB K1 RESISTANT K1 FAILURE K1 EFFICACY K1 SAFETY K1 MULTICENTER K1 Cancers JF 10.1038/bjc.2017.290 LK http://hdl.handle.net/10138/228557 DO http://hdl.handle.net/10138/228557 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)